There has been some success in targeting several TAAs in preclinical ovarian cancer studies including MUC16,27 mesothelin,28, 29, 30 follicle stimulating hormone receptor31, 32 and folate receptor α.33 This evidence concerns the gene MUC16 and ovarian carcinoma.